May 31st, 2013
Today’s announcement by Achillion Pharmaceuticals that it’s testing a new treatment for hepatitis C is promising news. The company plans to complete regulatory submissions during the first quarter of 2014, with first-in-human studies anticipated in the first half of 2014, followed by combination development in the second half of the year.
This new compound – sovaprevir – is a small molecule nucleotide and potentially very potent for the treatment of hepatitis C. It’s this, coupled with the fact that there aren’t many companies testing nucleotide treatments, that makes it an exciting prospect.
It’s an interesting time in the development of treatments for hepatitis C, and great news that another pharmaceutical company is focusing on developing treatments for the virus. Competition can only mean progress in the fight to prevent and cure hepatitis C.
Photo credit Truthout.org